Physician profile
John David Schmidt
NPI 1972760106
$4,061.58
in general payments reported to CMS, 2019-2025
26 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $280 · 2021: $549 · 2022: $461 · 2023: $674 · 2024: $910 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.25 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.91 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $438.23 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Fujifilm Healthcare Americas Corporation | $383.04 | 2020-2021 | |
| Genzyme Corporation | $375.27 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $327.93 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $286.47 | 2021-2025 | Tremfya, Stelara |
| Pfizer INC. | $116.85 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $92.82 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $79.16 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $78.89 | 2023 | Ibsrela |
| Gilead Sciences, INC. | $61.34 | 2021-2024 | |
| Qol Medical, LLC | $57.68 | 2021-2023 | Sucraid |
| Celltrion USA INC. | $49.09 | 2024-2025 | Zymfentra, Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.04 | 2019-2024 | Xifaxan |
| Celgene Corporation | $44.55 | 2021-2023 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $39.46 | 2024-2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $34.87 | 2022-2024 | |
| Organon LLC | $25.85 | 2021-2023 | Hadlima |
| Allergan, INC. | $23.75 | 2019 | |
| Madrigal Pharmaceuticals | $20.93 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $17.85 | 2022 | |
| Mirum Pharmaceuticals, INC. | $17.67 | 2024 | Livmarli |
| Novo Nordisk INC | $13.48 | 2025 | Wegovy |
| Sandoz INC. | $12.87 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $12.38 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John David Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.